Questions et réponses sur l'utilisation du rivaroxaban (Xarelto) dans la pratique [Questions and answers regarding the use of rivaroxaban in daily practice].
Details
Serval ID
serval:BIB_211D237D6A6D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Questions et réponses sur l'utilisation du rivaroxaban (Xarelto) dans la pratique [Questions and answers regarding the use of rivaroxaban in daily practice].
Journal
Revue Médicale Suisse
Working group(s)
groupe de travail RivaMoS Suisse, groupe Working Party on Haemostasis de la Société suisse d'hématologie
Contributor(s)
Wuillemin WA., Alberio LA., Angelillo-Scherrer A., Huber A., Tsakiris DA., Asmis LM., Fontana P., Korte W., Mendez A., Reber G., Stricker H., Studt JD., Tsakiris DA., Alberio LA., Angelillo-Scherrer A., Wuillemin WA., Asmis LM., Boehlen F., Korte W., Studt JD.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
9
Number
392
Pages
1375-1385
Language
french
Notes
Publication types: Consensus Development Conference ; English Abstract ; Journal Article Publication Status: ppublish
Abstract
Several new oral anticoagulants are now on the Swiss market and the general practitioner faces new challenges regarding the management of these new drugs. This consensus document aims to answer to the most frequently asked questions regarding rivaroxaban and covers different topics such as indications, initiation of treatment, drug-drug interactions and perioperative management.
Keywords
Administration, Oral, Anticoagulants/therapeutic use, General Practice, Humans, Morpholines/therapeutic use, Orthopedic Procedures/adverse effects, hic" UI="D013557">Switzerland, Thiophenes/therapeutic use, Treatment Outcome, Venous Thromboembolism/prevention & control
Pubmed
Create date
10/02/2015 12:10
Last modification date
20/08/2019 13:57
Usage data
